Current emerging MRI tools for radionecrosis and pseudoprogression diagnosis

Area of Science:

• Radiology
• Neuro-oncology
• Medical Imaging

Background:

• Differentiating post-treatment radiation effects (pseudoprogression, radionecrosis) from true tumor progression in brain tumors is critical for patient management.
• Conventional MRI has limitations in accurately assessing treatment response, despite its continued use in official criteria.
• Advanced MRI techniques offer potential improvements but face challenges in validation and standardization for routine clinical use.

Purpose of the Study:

• To review current MRI techniques for evaluating treatment response in brain tumors.
• To focus on the specific challenges posed by radiation-induced lesions.
• To introduce emerging techniques like Amide Proton Transfer (APT) imaging.

Main Methods:

• Review of current literature on MRI techniques for brain tumor treatment response assessment.
• Discussion of conventional MRI sequences and their limitations.
• Evaluation of advanced MRI techniques including perfusion, spectroscopy, and susceptibility-weighted imaging.
• Introduction of Amide Proton Transfer (APT) as a novel molecular imaging technique.

Main Results:

• Conventional MRI sequences are insufficient for reliably distinguishing radiation-induced lesions from tumor progression.
• Advanced MRI techniques, particularly perfusion imaging combined with spectroscopy and susceptibility-weighted imaging, enhance diagnostic accuracy.
• Amide Proton Transfer (APT) imaging shows potential for quantifying intracellular mobile proteins and peptides, offering new biomarkers for post-treatment evaluation.
• Lack of reproducibility and standardization remains a significant hurdle for widespread clinical adoption of advanced MRI techniques.

Conclusions:

• Advanced MRI techniques offer significant potential for improving the assessment of treatment response in brain tumors, especially in differentiating radiation-induced changes.
• Amide Proton Transfer (APT) imaging is a promising noncontrast technique that may provide valuable biomarkers in the post-therapeutic setting.
• Further validation and standardization are necessary to integrate these advanced techniques into routine clinical practice for brain tumor management.